Targeted degradation is an induced-proximity problem, not simply a binding problem. Both modalities can produce event-driven pharmacology, but neither guarantees degradation merely because the compound binds its intended partners.
Confirm removal of the full protein is the intended intervention in a relevant context.
Verify active machinery, localization, and substrate accessibility in the target tissue.
Establish that a productive ternary or induced interface can form.
Show the compound reaches the relevant compartment at sufficient free concentration.
Separate direct degradation from downstream or nonspecific protein loss.
Targeted protein degradation programs enter at very different stages. An early concept needs feasibility and route selection; an established chemical series needs a structural explanation for potency, selectivity, or resistance. Choose the scope that resolves the present decision.
A known target ligand and an E3-ligase ligand provide explicit starting points. Linker length, composition, exit vectors, and stereochemistry can be varied to sample ternary geometry.
A monovalent compound changes a recognition surface so a neo-interaction becomes favorable. Discovery may require phenotype-first screening, resistance mapping, proteomics, and structural deconvolution.
A weak binary interaction may be rescued by protein–protein contacts, while tight component binding can still yield an unproductive orientation. Structural models are hypotheses to test.
Each stage confirms a requirement before the next is built on top of it, so mismatches between biochemical, cellular, and proteomic results identify the actual bottleneck.
Discuss Your Study DesignShow that removing the target produces the intended biology and define a tolerable depth and duration of depletion.
Confirm active machinery, localization, substrate accessibility, and disease-state differences.
Choose PROTAC when modular ligand-based construction is feasible; favor a glue discovery route when an inducible interface or phenotype-led screen is more realistic.
Connect complex formation, ubiquitination, degradation, selectivity, exposure, and function.
Use mismatches between biochemical, cellular, and proteomic results to identify the actual bottleneck.
| Decision question | Evidence to collect | What can go wrong |
|---|---|---|
| Is removal of the protein biologically useful? | Genetic depletion, rescue constructs, time-resolved pathway readouts, disease-relevant models | Acute pharmacology differs from chronic genetic loss; phenotype reflects an off-target |
| Is a suitable ligase present and active? | Expression and protein abundance, subcellular localization, complex components, functional assays | RNA expression is mistaken for active ligase availability |
| Can a productive interface form? | Docking ensembles, structural data, mutagenesis, biophysical ternary-complex assays | A single low-energy pose is treated as the biological structure |
| Can the compound reach the compartment? | Permeability, intracellular concentration, efflux, stability, distribution | Potent cell-free activity fails because free intracellular exposure is inadequate |
| Is degradation selective and mechanistically linked? | Quantitative proteomics, ligase knockout/rescue, proteasome rescue, ubiquitination and washout studies | Protein loss is secondary to toxicity, transcriptional suppression, or stress |
Degraders add a sequence of required events beyond occupancy: induced complex formation, target placement near active ubiquitination machinery, a degradable ubiquitin signal, and proteasomal processing.
A single endpoint cannot explain why a compound works or fails. Combine complex formation, ubiquitination, time-resolved protein loss, and target-proximal function.
Most PROTACs still require a ligand for the target. Molecular glues may exploit surfaces without conventional pockets, but discovery and selectivity remain constrained by structural and cellular context.
Ternary geometry can improve selectivity beyond binary binding, yet recruited neosubstrates and downstream effects must be measured rather than assumed.
Ubiquitination geometry, complex dynamics, turnover, and proteasome processing matter. Long-lived complexes can help or hinder depending on the kinetic regime.
The authors demonstrated catalytic, event-driven protein knockdown by PROTACs, establishing that substoichiometric degradation—rather than target occupancy—is the design goal that matters for potency.
The authors showed that favorable protein–protein contacts and linker folding create cooperative recognition in the VHL–MZ1–BRD4 complex, linking ternary architecture to selective degradation.
The right evidence depends on how far the hypothesis has been characterized.
No. Binary affinity constrains engagement, but degradation also depends on induced-complex geometry, kinetics, ubiquitination competence, cellular exposure, ligase activity, proteasome processing, and target resynthesis. Affinity should be interpreted as one layer in an integrated evidence chain.
No. These ligases are common because recruiters and structural knowledge are available, but the human ubiquitin system contains many potential ligases and substrate receptors. A project should consider expression, localization, recruiter quality, catalytic geometry, tissue context, and selectivity before choosing an E3 system.
No. Protein abundance can fall through transcriptional, translational, stress-related, or nonspecific mechanisms. A convincing mechanism combines compound-dependent recruitment, ligase and proteasome dependence, increased ubiquitination, early selective depletion, resistant rescue, and a phenotype that follows the timing of target loss.
Share the target, available ligands, preferred E3 systems, structural data, assays, and project constraints. CD ComputaBio will propose a fit-for-purpose analysis across the stages you need. Related services: PROTAC Design and Development Service, Molecular Docking Service, Molecular Dynamics Simulation.
Submit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk
